MEETING CHANGE TO VIRTUAL: Antibodies as Drugs
Scientific Organizers: Pierre Bruhns, Patrick C. Wilson, Esther Breij and David P. Humphreys
Date: January 27 - 30, 2021
Location: Virtual at your computer
For important information on the coronavirus, please click here
Therapeutic antibodies continue to largely populate the list of top biologic drugs. They revolutionize the treatment of pathologies falling into major disease areas, which include cancer, chronic inflammatory diseases, allergy and infectious diseases. As more antibodies are being tested to treat an expanding number of pathologies, there has also been a concomitant increase in the frequency of resistance and escape mechanisms. Thus, researchers are exploring alternative concepts to prevent unresponsiveness or treat resistant patients. Therefore, not only are new methodological and technological advances being developed, paradigm-shifting concepts are being developed in order to face these challenges. This conference in the Keystone Symposia series on Antibodies as Drugs aims to present the state-of-the-art in antibody therapeutics, repertoires and deep learning, bispecific antibodies and engineering. This conference will provide a forum for extensive interactions between investigators from both industry and academia. Goals of this conference include discussion of recent breakthroughs in identifying therapeutics from patients, understanding vaccination and mode of delivery, modalities for half-life extensions and involvement of complement in antibody mode of action. It is anticipated that research in the field will showcase the rise of bispecific antibodies and highlight the technologies to develop them, improve their functionalities, and boost clinical efficacies, particularly in immune-oncology.
Meeting has either been cancelled or changed to a virtual eSymposia.Click here
for a listing of 2021 virtual Symposia or call our office for more information at 1-970-262-1230 or 1-800-253-0685.
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI154980-01
Funding for this conference was made possible (in part) by 1R13AI154980-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.